Medpace executive sells 7,500 shares at $600

Medpace Holdings, Inc. executive Susan E. Burwig, Exec.

Accepted by SEC EDGAR 07/29/2026 - 04:32 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Medpace Holdings, Inc. executive Susan E. Burwig, Exec. VP, Operations, reported selling 7,500 shares of Common Stock on 2026-07-28 at $600 per share in a transaction described as open market or private.

After the sale, she directly owned 62,984 shares. The trade was executed under a limit order placed during an open window period.

Insider Trade Summary

Net Seller: 7,500 shares

Net Sell 1 txn

Insider BURWIG SUSAN E

Role Exec. VP, Operations

Sold 7,500 shs ($4.50M)

Share of Position Sold 10.6%

Type	Security	Shares	Price	Value
Sale	Common Stock F1	7,500	$600.00	$4.50M

Holdings After Transaction: Common Stock — 62,984 shares (Direct)

Holdings Before and After: Common Stock, 70,484 to 62,984 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

Key Figures

Shares sold: 7,500 shares Sale price: $600.00 per share Transaction value: $4,500,000 +2 more

5 metrics

Shares sold 7,500 shares Common Stock sale on 2026-07-28 by Exec. VP, Operations

Sale price $600.00 per share Reported transaction price for the Common Stock sale

Transaction value $4,500,000 Approximate gross value of 7,500 shares sold at $600

Shares owned after sale 62,984 shares Directly owned Medpace Common Stock following the transaction

Net insider share change -7,500 shares Net shares sold across all non-derivative transactions in this filing

Key Terms

limit order, open window period, Rule 10b5-1, open market or private transaction

4 terms

limit order financial

"The transactions ... were effected pursuant to a limit order placed"

A limit order is an instruction to buy or sell a stock only at a specific price or better, giving you control over the exact price you pay or receive. It matters to investors because it acts like a price guard—similar to setting a maximum you’ll pay for an item at a store—so you avoid unexpected prices, though the trade may not happen if the market never reaches your limit.

open window period financial

"limit order placed by the Reporting Person during an open window period"

Rule 10b5-1 financial

"Document-level Rule 10b5-1 checkbox (aff_10b5_one) was not marked"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open market or private transaction financial

"transaction code S: Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medpace (MEDP) disclose for Susan E. Burwig?

Susan E. Burwig, Medpace’s Exec. VP, Operations, reported selling 7,500 shares of Common Stock at $600 per share on 2026-07-28, characterized as an open market or private transaction and executed via a limit order during an open window.

At what price did the Medpace (MEDP) executive sell her shares?

The reported sale price was $600.00 per share for 7,500 shares of Medpace Common Stock. This implies a gross transaction value of approximately $4,500,000, based on the per-share price and disclosed share quantity.

How many Medpace (MEDP) shares does Susan E. Burwig hold after this sale?

Following the reported transaction, Susan E. Burwig directly owned 62,984 shares of Medpace Common Stock. This post-transaction holding reflects her remaining direct ownership after selling 7,500 shares on 2026-07-28 at $600 per share.

Was the Medpace (MEDP) insider sale made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox was not marked, and a footnote states the trade was executed under a limit order placed during an open window period, rather than explicitly under a pre-arranged Rule 10b5-1 trading plan.

What does the limit order and open window period mean in the Medpace (MEDP) Form 4?

A footnote explains the sale occurred via a limit order placed during an open window period, indicating the order executed only at or above a specified price while the company’s trading window for insiders was open.

How much net insider share activity did Medpace (MEDP) report in this Form 4?

The Form 4 shows a net sale of 7,500 shares, with one reported sale transaction and no purchases or derivative exercises. All activity relates to Medpace Common Stock held directly by executive Susan E. Burwig.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURWIG SUSAN E

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OHIO 45227

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Exec. VP, Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		S(1)		7,500	D	$600	62,984	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Susan E. Burwig	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)